Difference between revisions of "Fluoxetine-doxepine"

From Psychiatrienet
Jump to: navigation, search
Line 13: Line 13:
 
* Fluoxetine and norfluoxetine slow the metabolism of doxepin via CYP2D6.  
 
* Fluoxetine and norfluoxetine slow the metabolism of doxepin via CYP2D6.  
 
* Norfluoxetine has a halflife of at least 1 week: it takes therefore 1 month for elemination.
 
* Norfluoxetine has a halflife of at least 1 week: it takes therefore 1 month for elemination.
* Start low, go slow for doxepin.}}
+
* Start low, go slow for doxepin.
 +
{{review}}}}

Revision as of 15:15, 21 October 2015

Fluoxetine
Type Antidepressant
Group SSRI
links
Medscape Fluoxetine
PubChem 3386
PubMed Fluoxetine
Kompas (Dutch) Fluoxetine
Wikipedia Fluoxetine
Doxepin
Type antidepressant
Group TCA
links
ATC-code N06AA12
Medscape Doxepin
PubChem 3158
PubMed Doxepin
Drugs.com doxepin
Kompas (Dutch) Doxepin
Wikipedia Doxepin

Switch medication from fluoxetine to doxepin.[2] [3]

Nietinrijdenbord.png Stop fluoxetine
  • Gradually reduce dosage of fluoxetine to a maximum of 20 mg/ day, when this dosage is > 20 mg/day.
  • When a dosage of 20 mg/day is reached, stop administration.
Eenrichtingbord.png Start doxepin

Caution is necessary for at least four weeks.

  • Day 1: start administration of doxepin in a low dosage of 25 mg/day.
  • Day 14: increase dosage of doxepin to 50 mg/day.
  • Day 28: increase dosage of doxepin to 75 mg/day.
Infobord.png More information
  • Fluoxetine and norfluoxetine slow the metabolism of doxepin via CYP2D6.
  • Norfluoxetine has a halflife of at least 1 week: it takes therefore 1 month for elemination.
  • Start low, go slow for doxepin.
  • This switch is currently being reviewed.
  1. 1.0 1.1 1.2 1.3 1.4 KNMP; Informatorium Medicamentorum 2023; Monografie "doxepine" (Dutch)
  2. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  3. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.